DDInter1242 DDInter1658
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticosteroids or other agents in asthma step therapy. Regardless, in 2008-2009, there were FDA-led investigations into the possibility of montelukast to elicit neuropsychiatric effects like agitation, hallucinations, suicidal behaviour, and others in individuals who used the medication. And although these kinds of effects are currently included in the official prescribing information for montelukast,[L6301,L6304,L6307,L6310,L6325,L632
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Montelukast {u} (Compound) treats {v} (Disease) chronic obstructive pulmonary disease
Montelukast {u} (Compound) binds {v} (Gene) CYP2C8
Montelukast {u} (Compound) upregulates {v} (Gene) SESN1
Montelukast {u} (Compound) is included by {v} (Pharmacologic Class) Leukotriene Receptor Antagonists
Montelukast {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Montelukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Montelukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminoglutethimide
Montelukast (Compound) treats chronic obstructive pulmonary disease (Disease)
Montelukast (Compound) binds CYP2C8 (Gene)
Montelukast (Compound) upregulates SESN1 (Gene)
Montelukast (Compound) is included by Leukotriene Receptor Antagonists (Pharmacologic Class)
Montelukast (Compound) causes Aspartate aminotransferase increased (Side Effect)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide